IT Strategy and Architecture: Creating an Enterprise Model to Support IT Strategic Planning

The IT strategy of many organisations has evolved over a period of time rather than been purposely defined, and in many cases is not actually documented. However, businesses and customers expect IT systems and services to meet the requirements of the organisation with the consequent need for translating the organisation’s objectives into IT strategy and capabilities, in order that together they can respond to the rapidly-changing environment. The adoption of an end-to-end architectural approach can help with IT strategy planning and execution.

KEY FINDINGS
There needs to be a clear understanding of the enterprise goals and the role that the business expects IT to play.
To remain competitive, organisations must urgently address the growing dislocation between strategy and IT deliverables.
Defining an IT strategy is of little value if organisations are unable to measure the effectiveness of that strategy in delivering value.
Enterprise Architecture must take a leadership role in IT strategy and service delivery.
Special attention should be paid to the people and process aspects of Enterprise Architecture.
An enterprise model needs to be communicated in each stakeholder’s ‘language’, as well as being relevant to senior management and solution architects.
Architecture can benefit from a metrics-based and performance analytics-driven approach.
For architecture to become a respected discipline there needs to be additional encouragement.
Organisations should take a portfolio-based approach to selecting IT investments.

CATALYST
IT organisations are under pressure to develop an effective strategy and to deliver services that can support changing requirements. An architectural approach can offer a useful framework within which organisations can plan and execute IT strategy.

ANALYSIS

Introduction

The IT strategy of many organisations has evolved over a period of time rather than been purposely defined, and in many cases is not actually documented. However, businesses and customers expect IT systems and services to meet the requirements of the organisation with the consequent need for translating the organisation’s objectives into IT strategy and capabilities, in order that together they can respond to the rapidly-changing environment. The adoption of an end-to-end architectural approach can help with IT strategy planning and execution.

In order to improve competitiveness, organisations must urgently address the growing dislocation between the business requirements and IT deliverables. This issue is directly impacting the enterprise’s ability to make quick, accurate decisions and is causing slow implementation of the IT strategy. The gap between IT capability and business needs cannot be allowed to continue. Additionally, many organisations are struggling to highlight the value that IT is delivering to the businesses. Enterprise Architecture provides a useful framework within which organisations can address governance requirements by better planning and the ability to prove compliance, as well as providing an improved understanding of the value of technology investments.

Business Issues

Many IT strategies are assessed and updated yearly as part of the budgeting process and Enterprise Architecture initiatives are developed as isolated, ‘ivory-tower’ endeavours. A better method is to adopt an iterative process, and to use the opportunity to begin to translate IT strategy into reusable deliverables through architecture. This involves the adoption of an architectural approach, rather than the use of tactical undertakings where there is a possibility of reverting back to a siloed mentality, as there is no mechanism in place to interpret strategy and control delivery through the use of architecture, policies, patterns, and common standards.

The IT strategy must address the capabilities required to design and deploy IT solutions, and the way in which the organisation will exploit these capabilities to create business value, both of which must be measured to gauge their success. The IT capabilities include technology infrastructure, business applications, IT processes and services, and skills, which enable a portfolio of IT-enabled business projects and programmes. A balanced scorecard approach provides a unified view of IT strategy performance across all of these dimensions.

Enterprise Architecture is an important company asset that has to be managed and updated on an ongoing basis to ensure relevance is maintained. To successfully adopt Enterprise Architecture there has to be complete buy-in across the entire organisation, with an understanding of the allocation of the roles and responsibilities. Technology and business areas within the enterprise must work together to ensure that the architecture keeps in line with the strategic objectives of the company and adequately reflects the IT services available now and planned for the future.

Attempts to align IT strategy with an abstract business vision or strategy are doomed to failure, and within the Enterprise Architecture domain, an enterprise model is a way to deconstruct business strategy and objectives into something that is more tangible, and into which the other elements of the business environment can be integrated. Butler Group recommends an incremental approach based on continuous improvement when developing an enterprise model, focused at meeting the business objectives and where value can be delivered quickly. This can be achieved by the model only depicting just enough architecture to enable decisions to be made and by growing the model iteratively over time.

The belief is that Enterprise Architecture and engaging with senior management to define a top-level business architecture and enterprise model has become a necessity for any organisation wishing to effectively interpret IT strategy, and successfully utilise technology as an enabler for business agility and change.

http://www.aarkstore.com/reports/IT-Strategy-and-Architecture-Creating-an-Enterprise-Model-to-Support-IT-Strategic-Planning-13948.html

WiMAX:The Broadband Wireless MAN – Aarkstore Enterprise

WiMAX, the Broadband Wireless MAN reports on the WiMAX industry and global market. Its 18-page, succinct Executive Summary addresses key WiMAX applications, standards, major WiMAX investors and their vested interests, WiMAX impact on evolving Wi-Fi, the appeal of the 700 MHz band auctioned by the FCC, WiMAX evolution, the WiMAX Forum and its mission, and a five-year WiMAX market forecast. Abundant tables and illustrations facilitate an at-a-glance, clear understanding of the subject under discussion.

WiMAX, the Broadband Wireless MAN defines and describes WiMAX, the exciting new broadband wireless access (BWA) technology for metropolitan area networks (MANs), with service now being deployed in the US by Sprint Nextel and Clearwire — who plan to build a nationwide WiMAX network — and by other carriers and service providers on a global basis. The study cites the importance and appeal of WiMAX as a subscriber-based, broadband wireless technology for fixed, portable, nomadic, and mobile applications with convergence for data, voice, and video (triple-play) applications.

For more information, please visit :
http://www.aarkstore.com/reports/WiMAX-The-Broadband-Wireless-MAN-1940.html

Global Biomaterial Market – Aarkstore Enterprise

The biomaterials market is defined and explained through the introduction of biotechnology and advances in the understanding of human tissue compatibility. Developing from bio-inert materials to biodegradable materials, biomaterials are widely used in medical devices, tissue replacement, and surface coating applications. The major segments in biomaterials market are ceramics, metals, polymers, and composites. Biomaterials products are classified into orthopedic, cardiovascular, gastrointestinal, wound care, urology, plastic surgery, and others. Reconstructive surgery and orthobiologics are the dominant segments in orthopedic biomaterials market.

Biomaterials products had a market size of $25.5 billion in 2008, and the biomaterial device market size was $115.4 billion in the same year, and is expected to reach $252.7 billion in 2014. This massive revenue potential highlights the immense opportunity in the market. In the next five years, the biomaterials market is expected to grow at a CAGR of 15%.

Improved patient benefits form the most important factor stimulating market growth for biomaterials. The other market drivers are increase in aging population, rising awareness, shorter product approval time, and larger application area. However, the lack of tissue availability and proper reimbursement facilities are restraining the growth of the biomaterials market.

Improvement in fabrication technology and new product development at competitive prices will be the key to future market growth. The U.S. and Europe hold a major share of the global biomaterials market; while emerging economies such as China, India, Japan, Brazil, Russia, and Romania represent a high growth rate.

REPORT DESCRIPTION

This report uses the term biomaterials to refer to the materials used in the human body. The report segments the global biomaterial market as follows:

• Biomaterials product market
Orthopaedic, cardiovascular, gastrointestinal, wound care, plastic surgery, urological and others

• Biomaterials ingredient market
Metals, polymers, ceramics, composites

• Biomaterials application market
General, surgical appliances and supplies, surgical and medical instruments, dental products, electro-medical equipment, in-vitro diagnostic products, and other applications

Each section will provide market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide more than 100 market tables for various geographic regions covering the sub-segments and micro-markets. In addition, the report also provides more than 50 company profiles for each of its sub-segments.

What makes our reports unique?

- We provide the longest market segmentation chain in this industry- not many reports provide market breakdown upto level 5.
- Each report is about 250 pages with 100+ market data tables, 40 competitive company profiles, analysis of 300 patents and a minimum of 50 micro markets, which are collectively exhaustive and mutually exclusive.
- No single report by any other publisher provides market data for all the segments viz products, services, applications, ingredients, technology, and stakeholders in a single report for all the four geographies – US, Europe, APAC, ROW.
- We provide 10% customization. Normally it is seen that clients do not find specific market intelligence that they are looking for. Our customization will ensure that you necessarily get the market intelligence you are looking for and we get a loyal customer.
- 15 pages of high level analysis including benchmarking strategies, best practices and the market’s cash cows (BCG matrix). We conduct detailed market positioning, product positioning and competitive positioning. Entry strategies, gaps and opportunities are identified for all the stakeholders.
- Comprehensive market analysis for the following sectors:
Pharmaceuticals, Medical Devices, Biotechnology, Semiconductor and Electronics, Energy and Power Supplies, Food and Beverages, Chemicals, Advanced Materials, Industrial Automation, and Telecom and IT. We also analyze retailers and super-retailers, technology providers, and research and development (R&D) companies.

Key questions answered

- Which are the high-growth segments/cash cows and how is the market segmented in terms of applications, products, services, ingredients, technologies, and stakeholders?
- What are market estimates and forecasts; which markets are doing well and which are not?
- Where are the gaps and opportunities; what is driving the market?
- Which are the key playing fields? Which are the winning edge imperatives?
- How is the competitive outlook; who are the main players in each of the segments; what are the key selling products; what are their strategic directives, operational strengths and product pipelines? Who is doing what?

Powerful Research and analysis

The analysts working come from renowned publishers and market research firms, globally, adding their expertise and domain understanding. We get the facts from over 22,000 news and information sources, a huge database of key industry participants and draw on our relationships with more than 900 market research companies across the world. We are inspired to help our clients grow by providing qualitative business insights with our huge market intelligence repository.

For More Information, Kindly Visit :
http://www.aarkstore.com/reports/Global-Biomaterial-Market-2009-2014–27516.html

The Scandinavian Pharmaceutical Market Outlook to 2013: Policy environment, market structure, pipeline analysis, growth opportunities – Aarkstore Enterprise

The Scandinavian Pharma Market Outlook to 2013: Policy environment, market structure, pipeline analysis and growth opportunities

The Scandinavian healthcare system and pharmaceutical market is well regulated, with the state bearing responsibility for a large proportion of an individual’s pharmaceutical expenses. Solidarity and equality are the ideological basis of these welfare states, and a significant public commitment exists towards ensuring access to high quality health care for all citizens. Sweden and Denmark have been the two biggest pharma and biotech markets in Scandinavia, while regional players such as Novo Nordisk have laid the foundations for this industry in the region.

‘The Scandinavian Pharmaceutical Market Outlook to 2013’ is a report published explores the healthcare systems and policy environments of Denmark, Norway, Sweden and Finland. This report examines the region’s market potential by assessing historic epidemiological data, sales trends, competitive intelligence and clinical data across each major country. The growth drivers of the region are identified and forecasts for major prescription drugs and markets are provided for the period 2009-13. The competitive landscape of the Scandinavian market is also evaluated, with the region’s five leading companies being assessed based upon their marketed product portfolios and R&D pipelines in order to forecast their future competitive positions.

Key Findings

The Scandinavian pharma market recorded sales of $10.1bn in 2007, a 16% increase over 2006. Sweden had the largest market share (38%), followed by Finland (23%), Denmark (22%), and Norway (17%). These countries possess developed infrastructures, advanced technologies, R&D support and business friendly cultures. Pfizer led the Scandinavian market in 2007 with sales of $696m, a 6.3% increase over 2006.

Pfizer has a significant presence in all four Scandinavian markets and in the leading therapeutic areas of the region. Drugs for the treatment of CNS disorders are the largest product class in Scandinavia, with a market share of 20.7% in 2007. Cancer and cardiovascular diseases are the next largest therapeutic categories in the region.

Well-developed biotech and life sciences clusters across the Scandinavian region enable world-class research and provide pools of well-educated personnel and versatile facilities to support start-up companies.

Parallel trade has become a major concern for the profitability of Scandinavia-based Pharma companies in recent years. Factors driving this include lower prescription drug expenditures sought by payors and parallel traders’ strategies benefit from price differentials for drugs across different countries.

Use this report to…

• Compare the healthcare markets of key Scandinavian countries with this report’s macroeconomic analysis of infrastructure, per capita health expenditure and Pharma sales growth vs. GDP growth across Sweden, Finland, Denmark and Norway.

• Understand how healthcare policy environments vary across the region with this report’s examination of drug approval processes, pricing regulations and reimbursement policies in each major country.

• Identify which indications have the greatest potential to provide franchise growth with this report’s evaluation of major therapy/sub-therapy areas and leading brands, including forecast sales over the period 2009-2013.

• Measure the performances and prospects of leading companies in the Scandanavian area with this report’s strategic analysis of leading pharma corporations based on sales focus by drug class, currently marketed products and R&D pipeline portfolios.

Explore issues including…

The threat to EU health spending. Pharma activity in the Scandinavian market is focused around cost containment, but in recent years the consumption of generics and parallel imports has slowly increased. A new pricing regime linked to other European countries has also had a moderating effect on price levels in Scandinavian countries over recent years.

Higher licensing deal values. Competition for promising projects (particularly drugs that have established solid proof-of-concept data) has not only boosted the deal values overall, but also increased the quantity and average value of deals in the early stages of product development.

Parallel trade influencing pricing. The prevalence of parallel trade is having a significant impact upon state expenditure on drugs and consumer prices. In Sweden, parallel imports have been included as substitutable products in accordance with the generic substitution policy, giving significant boost to parallel imported products in the country.

Support for generic substitution of patented drugs. A report by the National Trade Estimate of the United States Trade Representative (USTR) made special mention of Finland, due to the country’s Pharma Pricing Board not always waiting for the expiry of the analogous process patent before taking action.Discover…

• What will be the major growth drivers in the Scandinavian pharma market over 2009-13?

• Which companies were the winners and losers in the Scandinavian pharma market in 2007?

• Which companies will become key players over 2009 -13?

• Which products will be affected by generic competitors over the period 2009-13?

• Which pipeline products will be the growth drivers of the future?

• Which therapy areas and indications have the highest market potential over 2009-13?

• How will the Scandinavian pharma market’s competitive landscape change by 2013?

 For more information, kindly visit :
http://www.aarkstore.com/reports/The-Scandinavian-Pharmaceutical-Market-Outlook-to-2013-Policy-environment-market-structure-pipeline-analysis-growth-opportunities-13979.html

Key Trends in Offshoring Pharmaceutical R&D: Company strategies, emerging markets and impact on ROI – Aarkstore Enterprise

Key Trends in Offshoring Pharmaceutical R&D: Company strategies, emerging markets and impact on ROIs

Offshoring and outsourcing have become an increasingly critical contributor to pharma and biotech R&D strategies in recent years. They enable companies to focus on core competencies such as drug discovery or technology development whilst contracting out non-core processes to experts, often at lower costs. As offshore investments begin to mature and provide returns on investment, the opportunity to migrate individual components or whole segments of R&D portfolios will continue to rise.

‘Key Trends in Offshoring Pharmaceutical R&D’ is a report published evaluates the offshore R&D strategies that can reduce development times and improve productivity, with analysis of a variety of strategic partnerships, academic collaborations, and outsourcing opportunities. This report identifies emerging areas of technological and scientific significance across the globe and examines the offshore strategies and investments of the top 20 pharma and biotech companies across Asia, Australia, Central and Eastern Europe, Latin America and the Far East. This report also provides a financial and managerial valuation of leading companies based on their P/E ratio, return on assets (ROA) and return on investment (ROI) and measures company performance against the healthcare industry, pharmaceutical and biotechnology sectors and leading shares of the S&P500.

Key Findings

• Companies that have allocated over 60% of their R&D expenditure offshore have displayed greater shareholder return, operating margins, market capital growth and return on assets.

• The US currently attracts 53% of total industry R&D spend, however it is forecast that 20% of this expenditure will migrate to Asia Pacific by 2010. Australia, China and Singapore are emerging as key areas for scientific and technological investment.

• Leading pharma and biotech companies have undergone major R&D restructuring over the last five years and now adopt a focused, streamlined global approach which is increasingly reliant on offshore strategic partnerships, academic collaboration and outsourcing to establish networks of scientific expertise.

• Scientific and technological excellence within emerging economies is a key incentive for offshore investment, enabling companies to enhance innovation and productivity within their R&D programs.

• Managerial expertise is a critical factor driving the success of offshore investments, helping leading pharma and healthcare companies to outperform their peers and the S&P 500 index in 2008.

Use this report to…

• Assess the offshore R&D strategies of the top 20 pharma and biotech companies with this report’s analysis of offshore investment and deal trends over the last five years.

• Discover which geographic regions have the greatest potential for offshore R&D investment by identifying key areas of technological, scientific and academic expertise across Asia Pacific, Australia, Eastern Europe, Latin America, the Middle East and South Africa.

• Measure how the offshore strategies of the top 20 pharma and biotech companies have influenced their R&D productivity and efficiency with this report’s financial and managerial performance review, comparative analysis of healthcare/pharma/biotech sectors and S&P500 index assessment.

• Identify the key drivers and opportunities for offshore investment with this report’s analysis of major offshoring trends and R&D developments.

Explore issues including…

Shifting focus of R&D strategies. The industry has become more globalized in its R&D approach as part of efforts to improve productivity and efficiency. Networks of offshore partnerships and academic collaborations are now enabling companies to harness external expertise on a project by project basis.

Offshore investment in emerging economies. Companies are increasingly turning to emerging countries to counter the slowing growth of US and European markets. Investing in offshore R&D facilities provides companies with local expertise and a greater understanding of local economies.

Offshore opportunities in tertiary economies. The success of commercial opportunities in emerging markets has expanded the regional scope of investment, with Australia, Israel and Singapore all seen to provide labour arbitrage and access to specialists.

Focused managerial directives are critical. Successful R&D performance is underpinned by a streamlined R&D strategy which is well managed by a team of scientists, technologists and non-scientists which can guide global networks ensuring early go/no go decision making which builds on the core competencies of both internal and external researchers.

Discover…

• Which countries are attracting offshore investment?

• Which areas of research and technology are attracting offshore investment?

• How are the leading pharma and biotech companies changing their R&D programs?

• Which major companies and academic institutions have attracted offshore investment?

• What factors are driving offshore investment?

• What is the financial performance of the leading pharma and biotech companies based on P/E ratio compared to their peers and the S&P500?

• Which companies have delivered the best return on assets and return on investment during the last five years?

• How will offshore investment influence R&D productivity in the future?

 For more information, kindly visit :
http://www.aarkstore.com/reports/Key-Trends-in-Offshoring-Pharmaceutical-R-D-Company-strategies-emerging-markets-and-impact-on-ROI-13950.html

Fighting the Market Slowdown in Alcoholic Drinks: Growth hotspots, innovation and changing consumer preferences – Aarkstore Enterprise

Fighting the Market Slowdown in Alcoholic Drinks – Growth hotspots, innovation and changing consumer preferences

Report Overview…

The global market for alcoholic drinks was worth US$979bn in 2007, equivalent to 1,460bn servings. Although sales of alcoholic drinks are typically relatively immune from recessions, although the current economic downturn has coincided with a period of higher inflation and rising prices which have dampened demand for alcoholic drinks. However, the downturn itself is likely to have a positive effect on demand. In developed markets consumers will spend more time socializing and drinking at home. In emerging markets consumers will buy fewer consumer durables and spend part of the savings on everyday treats such as beer, wine and spirits.

‘Fighting the Market Slowdown in Alcoholic Drinks: Growth hotspots, innovation and changing consumer preferences’ is a new report published by Business Insights that evaluates which regions, countries and products are expected to grow over the next five years. This report provides an understanding of underlying consumer purchasing triggers in alcoholic drinks as well as an in-depth analysis of regulatory developments and product innovations on a domestic and global scale.

Key Findings…

The volume of alcoholic drinks consumed in western Europe is forecast to decline over the period 2007-2012 by an average of 0.2% per annum.

Between 2007 and 2012 the annual sales of spirits globally is forecast to increase by over 1bn liters. 70% of this increase will take place in Asia-Pacific markets.

China is the largest beer market in the world, having overtaken the US in recent years. This growth is being driven by a growing middle class that has increasingly Western tastes plus a shift away from traditional spirits consumption.

Globally, there will be an additional 18.7bn liters of beer/cider/FABs sold in 2012 compared to 2007. 62% of this increase will take place in Asia-Pacific and 29% will be in Eastern Europe. Less than 8% of this growth will be in North America and these regional rises will be a result of the decline in the Western European market.

Use this report to…

• Quantify key beer, wine and spirits markets and growth potential based on market value and volume sales data between 2007 and 2012 by category, region, country and product tag.
• Improve the targeting and effectiveness of your NPD strategy using this report’s analysis of product launch data of 4,800 beer, wine and spirits products launched globally between 2005-2008.
• Identify key trends that are shaping the beer, wine and spirit market, and evaluate the trends likely to become important over the coming years.
• Understand consumption patterns of alcoholic drinks with this report’s detailed analysis of the changing share of throat held by beer, wine and spirits across key regions.

Key issues…

Changing consumer consumption. In terms of number of servings, spirits is the largest sector (accounting for 46% of servings), ahead of beer (43% of servings). The latter is expanding at the expense of the former and the two will almost be equal by 2012. Wine only accounts for a steady 11% of servings.

Emerging beer markets. Nine out of the ten countries with the highest levels of predicted sales over the next five years are emerging markets.

Premiumization. Multinational operators are facing increasing competition from local players that have started to develop their own premium and super-premium brands with high quality products, packaging and promotion.

Ageing population. In developed markets, the proportion of consumers in senior age groups continues to increase, and this will be reflected in increased upscale product sales. This is due to the population group having a more sophisticated palate.

Your questions answered…

• How is the share of throat held by beer, wine and spirits changing over time?
• Which alcoholic drinks categories and regions offer the greatest sales growth potential to 2012?
• What are the key trends that will shape the future of the beer, wine and spirits markets?
• Where will growth in the beer market be most significant?
• Which beer, wine and spirits product categories are growing fastest?
• What are the key consumer drivers of growth of beer, wine and spirits sales in emerging countries?
• Who is driving innovation in alcoholic drnks market?
• How is the growing trend of premiumization impacting product development and new product launches?

For more information, kindly visit :
http://www.aarkstore.com/reports/Fighting-the-Market-Slowdown-in-Alcoholic-Drinks-Growth-hotspots-innovation-and-changing-consumer-preferences-13961.html

Global Security Software Market in Retail Industry 2008-2012 – Aarkstore Enterprise

Security software helps organizations achieve higher scalability in terms of data management and data operations. It’s features such as easy & protected access to content and ease of sharing content help organizations scale up their revenue. At present, organizations all over the world are undergoing a consolidation phase. This has led to the creation of huge data centers, which are managing complex information for enterprises. This data is termed as ‘knowledge’, and its security is of paramount issue for enterprises. According to a study, year 2008 witnessed a significant increase in security attacks by cybercriminals, whereas breaches through malwares and Trojans have increased by multi folds. Also, it has been found that a majority of the security breaches in 2008 was through internal resources.

Security issues are more prevalent in the retail industry wherein databases grow on a daily basis. Thus, security software that are protecting accessibility, integrity, and data transfer in organizations, are becoming a popular choice for such enterprises. Their easy to operate features, requirement specific solutions, and reliability have turned them as essential requirement for enterprises.

The report by TechNavio Insights forecasts the size of the Global Security Software Market in Retail Industry over the period 2008-2012. It segments the market into various geographic regions (representing the market size for each of these regions). Further, it discusses the key market trends, drivers and challenges of the Global Security Software Market in the Retail Industry, and profiles some of the key vendors of this Industry.

TechNavio Insights is a set of reports based on TechNavio – a market intelligence platform for the IT industry. It builds on the intelligence available within TechNavio, and leverages on the custom research experience of the ‘Technology Navigators’. TechNavio is built on years of experience of Infiniti Research in deep dive custom research and consulting for over 30 Fortune 500 companies and numerous large and mid-sized companies.

For more information, kindly visit :
http://www.aarkstore.com/reports/Global-Security-Software-Market-in-Retail-Industry-2008-2012-19489.html

Welcome to Aarkstore Market Research Aggregation

We specialize in providing online market business information on market research reports, books, magazines, conference booking at competitive prices, and strive to provide excellent and innovative service to our customers. We are built on the premise that reading is valuable, capable of stirring emotions and firing the imagination. Whether you’re looking for new product trends or competitive analysis of a new or existing market, Aarkstore.com has the best resource offerings and the expertise to make sure you get the right product every time. 
 
http://www.aarkstore.com

Wealth Management in India by Aarkstore Enterprise

Introduction

Wealth management is classified as a type of financial planning tool that provides the corporates and their families with private banking, asset management, legal resources,real estate planning, investment management and portfolio management with the goal of sustaining and growing long-term wealth. Wealth management service providers have segmented the Indian market into four categories: the mass market (investible surplus USD5,000 to 25,000); the mass affluent (USD25,000 to 1 million); the high-net-worth (USD1 million to 30 million) and the ultra-high net worth (greater than USD30 million).

Key Findings & highlights

During the second half of 2007, there was a contrasting difference between the matured and emerging economies where emerging market captured the major portion of wealth management.

In 2007, the global economy grew by 5.1%, down slightly from the 5.3% global growth in 2006.

The United States had one of the world’s lowest savings rates in 2007

The population of HNWIs reached 10.1 trillion in 2007

The Indian market has outperformed global markets significantly and formed new highs coincided with a continuous increase in derivatives position which peaked at over Rs1 trillion.

Reasons to Buy

Spot Investment opportunities

Reveals the factors that hamper growth of Wealth Management Industry in India

Get a thorough understanding about the industry and prevent further losses

Know the corrective measures for sustainable growth in the industry

For more information, kindly visit :
http://www.aarkstore.com/reports/Wealth-Management-in-India-12557.html

Pharma Business Management Insight By Aarkstore Enterprise

 Introduction

The Indian pharmaceutical industry grew at 13% during 2003-07 and the market size is estimated to be US$ 9.77 billion in 2007-08. Exports constitute a significant part of the pharmaceutical industry. Pharmaceutical exports from India are expected to grow at a CAGR of 18.5% during FY08-FY12, particularly driven by multibillion dollar patent expirations and growth in global generics market. While the growth path of pharmaceutical industry is well defined, it is important to know how the industry needs to be managed. An industry, which is driven by global demand, has more reasons to adopt smart and efficient management practices. Examples are galore in India where many Indian pharmaceutical companies are known to be multinationals, following the best management practices.

However, a comprehensive knowledge of pharmaceutical management is required for those aspiring for a career in pharmaceutical industry. A broad-based knowledge about various aspects of management would help to start the career with confidence. In view of the potential of Indian pharmaceutical industry and the expanding global outsourcing market in pharmaceuticals, Cygnus Research has come out with the report titled Pharma Business Management Insight for which an editable PPT is also available providing major information

Reasons to Buy

Covers concepts of production management in a pharma company, marketing and its distribution channels, inventory management and its importance, and above all, environment management, which is critical to any pharma company

Provides insight into the key concepts of pharma business management in a comprehensive manner

Prepares students and budding management executives to face the industry confidently

For more information, kindly visit :
http://www.aarkstore.com/reports/Pharma-Business-Management-Insight-12516.html